Abstract
The complexity of tumor biology necessitates a multimodality approach that targets different aspects of tumor environment in order to generate the greatest benefit. IFN-inducible T cell α chemoattractant (ITAC)/CXCL11 and IFN-inducible protein 10 (IP10)/CXCL10 could exert antitumor effects with functional specificity and thus emerge as attractive candidates for combinatorial strategy. Disappointedly, a synergistic antitumor effect could not be observed when CXCL10 and CXCL11 were pooled together. In this regard, we seek to improve antitumor efficacy by integrating their individual functional moieties into a chemokine chimeric molecule, designated ITIP, which was engineered by substituting the N-terminal and N-loop region of CXCL10 with those of CXCL11. The functional properties of ITIP were determined by chemotaxis and angiogenesis assays. The antitumor efficacy was tested in murine CT26 colon carcinoma, 4T1 mammary carcinoma and 3LL lung carcinoma. Here we showed that ITIP not only exhibited respective functional superiority but strikingly promoted regression of established tumors and remarkably prolonged survival of mice compared with its parent chemokines, either alone or in combination. The chemokine chimera induced an augmented anti-tumor immunity and a marked decrease in tumor vasculature. Antibody neutralization studies indicated that CXCL10 and CXCL11 moieties of ITIP were responsible for anti-angiogenesis and chemotaxis in antitumor response, respectively. These results indicated that integrating individual functional moieties of CXCL10 and CXCL11 into a chimeric chemokine could lead to a synergistic antitumor effect. Thus, this integration strategy holds promise for chemokine-based multiple targeted therapy of cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Rabinovich GA, Gabrilovich D, Sotomayor EM (2007) Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25:267–296. doi:10.1146/annurev.immunol.25.022106.141609
Kerbel RS (2008) Tumor angiogenesis. N Engl J Med 358(19):2039–2049. doi:10.1056/NEJMra0706596
Dougan M, Dranoff G (2009) Immune therapy for cancer. Annu Rev Immunol 27:83–117. doi:10.1146/annurev.immunol.021908.132544
Disis ML, Bernhard H, Jaffee EM (2009) Use of tumour-responsive T cells as cancer treatment. Lancet 373(9664):673–683. doi:10.1016/S0140-6736(09)60404-9
Heath VL, Bicknell R (2009) Anticancer strategies involving the vasculature. Nat Rev Clin Oncol 6(7):395–404. doi:10.1038/nrclinonc.2009.52
Benny O, Fainaru O, Adini A, Cassiola F, Bazinet L, Adini I, Pravda E, Nahmias Y, Koirala S, Corfas G, D’Amato RJ, Folkman J (2008) An orally delivered small-molecule formulation with antiangiogenic and anticancer activity. Nat Biotechnol 26(7):799–807. doi:10.1038/nbt1415
Ma WW, Adjei AA (2009) Novel agents on the horizon for cancer therapy. CA Cancer J Clin 59(2):111–137. doi:10.3322/caac.20003
Balkwill F (2004) Cancer and the chemokine network. Nat Rev Cancer 4(7):540–550. doi:10.1038/nrc1388
Homey B, Muller A, Zlotnik A (2002) Chemokines: agents for the immunotherapy of cancer? Nat Rev Immunol 2(3):175–184. doi:10.1038/nri748
Strieter RM (2001) Chemokines: not just leukocyte chemoattractants in the promotion of cancer. Nat Immunol 2(4):285–286. doi:10.1038/86286
Gerard C, Rollins BJ (2001) Chemokines and disease. Nat Immunol 2(2):108–115. doi:10.1038/84209
Allen SJ, Crown SE, Handel TM (2007) Chemokine: receptor structure, interactions, and antagonism. Annu Rev Immunol 25:787–820. doi:10.1146/annurev.immunol.24.021605.090529
Fushimi T, O’Connor TP, Crystal RG (2006) Adenoviral gene transfer of stromal cell-derived factor-1 to murine tumors induces the accumulation of dendritic cells and suppresses tumor growth. Cancer Res 66(7):3513–3522. doi:10.1158/0008-5472.CAN-05-1493
Struyf S, Burdick MD, Peeters E, Van den Broeck K, Dillen C, Proost P, Van Damme J, Strieter RM (2007) Platelet factor-4 variant chemokine CXCL4l1 inhibits melanoma and lung carcinoma growth and metastasis by preventing angiogenesis. Cancer Res 67(12):5940–5948. doi:10.1158/0008-5472.CAN-06-4682
Chu Y, Yang X, Xu W, Wang Y, Guo Q, Xiong S (2007) In situ expression of IFN-gamma-inducible T cell alpha chemoattractant in breast cancer mounts an enhanced specific anti-tumor immunity which leads to tumor regression. Cancer Immunol Immunother 56(10):1539–1549. doi:10.1007/s00262-007-0296-1
Arenberg DA, Kunkel SL, Polverini PJ, Morris SB, Burdick MD, Glass MC, Taub DT, Iannettoni MD, Whyte RI, Strieter RM (1996) Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J Exp Med 184(3):981–992
Meiser A, Mueller A, Wise EL, McDonagh EM, Petit SJ, Saran N, Clark PC, Williams TJ, Pease JE (2008) The chemokine receptor CXCR3 is degraded following internalization and is replenished at the cell surface by de novo synthesis of receptor. J Immunol 180(10):6713–6724 (180/10/1673 [pii])
Colvin RA, Campanella GS, Sun J, Luster AD (2004) Intracellular domains of CXCR3 that mediate CXCL9, CXCL10, and CXCL11 function. J Biol Chem 279(29):30219–30227. doi:10.1074/jbc.M403595200
Angiolillo AL, Sgadari C, Taub DD, Liao F, Farber JM, Maheshwari S, Kleinman HK, Reaman GH, Tosato G (1995) Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 182(1):155–162
Clark-Lewis I, Mattioli I, Gong JH, Loetscher P (2003) Structure-function relationship between the human chemokine receptor CXCR3 and its ligands. J Biol Chem 278(1):289–295. doi:10.1074/jbc.M209470200
Campanella GS, Lee EM, Sun J, Luster AD (2003) CXCR3 and heparin binding sites of the chemokine IP-10 (CXCL10). J Biol Chem 278(19):17066–17074. doi:10.1074/jbc.M212077200
Schagger H, von Jagow G (1987) Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kda. Anal Biochem 166(2):368–379
McColl SR, Mahalingam S, Staykova M, Tylaska LA, Fisher KE, Strick CA, Gladue RP, Neote KS, Willenborg DO (2004) Expression of rat I-TAC/CXCL11/SCYA11 during central nervous system inflammation: comparison with other CXCR3 ligands. Lab Invest 84(11):1418–1429. doi:10.1038/labinvest.3700155
Sauty A, Colvin RA, Wagner L, Rochat S, Spertini F, Luster AD (2001) CXCR3 internalization following T cell-endothelial cell contact: preferential role of IFN-inducible T cell alpha chemoattractant (CXCL11). J Immunol 167(12):7084–7093
Dagan-Berger M, Feniger-Barish R, Avniel S, Wald H, Galun E, Grabovsky V, Alon R, Nagler A, Ben-Baruch A, Peled A (2006) Role of CXCR3 carboxyl terminus and third intracellular loop in receptor-mediated migration, adhesion and internalization in response to CXCL11. Blood 107(10):3821–3831. doi:10.1182/blood-2004-01-0214
Zhang G, Fahmy RG, diGirolamo N, Khachigian LM (2006) Jun sirna regulates matrix metalloproteinase-2 expression, microvascular endothelial growth and retinal neovascularisation. J Cell Sci 119(Pt 15):3219–3226. doi:10.1242/jcs.03059
Hillinger S, Yang SC, Zhu L, Huang M, Duckett R, Atianzar K, Batra RK, Strieter RM, Dubinett SM, Sharma S (2003) EBV-induced molecule 1 ligand chemokine (ELC/CCL19) promotes IFN-gamma-dependent antitumor responses in a lung cancer model. J Immunol 171(12):6457–6465
Zheng G, Liu S, Wang P, Xu Y, Chen A (2006) Arming tumor-reactive T cells with costimulator B7-1 enhances therapeutic efficacy of the T cells. Cancer Res 66(13):6793–6799. doi:10.1158/0008-5472.CAN-06-0435
Lecoeur H, Fevrier M, Garcia S, Riviere Y, Gougeon ML (2001) A novel flow cytometric assay for quantitation and multiparametric characterization of cell-mediated cytotoxicity. J Immunol Methods 253(1–2):177–187 (S0022-1759(01)00359-3 [pii])
Cole KE, Strick CA, Paradis TJ, Ogborne KT, Loetscher M, Gladue RP, Lin W, Boyd JG, Moser B, Wood DE, Sahagan BG, Neote K (1998) Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med 187(12):2009–2021
Proost P, Mortier A, Loos T, Vandercappellen J, Gouwy M, Ronsse I, Schutyser E, Put W, Parmentier M, Struyf S, Van Damme J (2007) Proteolytic processing of CXCL11 by CD13/aminopeptidase N impairs CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and endothelial cell migration. Blood 110(1):37–44. doi:10.1182/blood-2006-10-049072
Cox JH, Dean RA, Roberts CR, Overall CM (2008) Matrix metalloproteinase processing of CXCL11/I-TAC results in loss of chemoattractant activity and altered glycosaminoglycan binding. J Biol Chem. doi:10.1074/jbc.M800266200
Strieter RM, Burdick MD, Gomperts BN, Belperio JA, Keane MP (2005) CXC chemokines in angiogenesis. Cytokine Growth Factor Rev 16(6):593–609. doi:10.1016/j.cytogfr.2005.04.007
Cox JH, Dean RA, Roberts CR, Overall CM (2008) Matrix metalloproteinase processing of CXCL11/I-TAC results in loss of chemoattractant activity and altered glycosaminoglycan binding. J Biol Chem 283(28):19389–19399. doi:10.1074/jbc.M800266200
Luster AD, Greenberg SM, Leder P (1995) The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation. J Exp Med 182(1):219–231
Fernandez EJ, Lolis E (2002) Structure, function, and inhibition of chemokines. Annu Rev Pharmacol Toxicol 42:469–499. doi:10.1146/annurev.pharmtox.42.091901.115838
Thompson BD, Jin Y, Wu KH, Colvin RA, Luster AD, Birnbaumer L, Wu MX (2007) Inhibition of G alpha i2 activation by G alpha i3 in CXCR3-mediated signaling. J Biol Chem 282(13):9547–9555. doi:10.1074/jbc.M610931200
Zhao JM, Wen YJ, Li Q, Wang YS, Wu HB, Xu JR, Chen XC, Wu Y, Fan LY, Yang HS, Liu T, Ding ZY, Du XB, Diao P, Li J, Kan B, Lei S, Deng HX, Mao YQ, Zhao X, Wei YQ (2008) A promising cancer gene therapy agent based on the matrix protein of vesicular stomatitis virus. FASEB J 22(12):4272–4280. doi:10.1096/fj.08-110049
Sun Y, Finger C, Alvarez-Vallina L, Cichutek K, Buchholz CJ (2005) Chronic gene delivery of interferon-inducible protein 10 through replication-competent retrovirus vectors suppresses tumor growth. Cancer Gene Ther 12(11):900–912. doi:10.1038/sj.cgt.7700854
Fushimi T, Kojima A, Moore MA, Crystal RG (2000) Macrophage inflammatory protein 3alpha transgene attracts dendritic cells to established murine tumors and suppresses tumor growth. J Clin Invest 105(10):1383–1393. doi:10.1172/JCI7548
Acknowledgments
We thank Lin Xu, Zhenggang Jiang, Bo Gao for technical assistance and valuable suggestions, Peng Hu for his help with animal studies and Feng Zhang for FACS advice. This research was funded in part by China NSFC grant (30890141, 30872355), the Major State Basic Research Development Program of China (2007CB512401) and Program for Shanghai Outstanding Medical Academic Leader (LJ06011).
Conflict of interest
The authors declare no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wang, P., Yang, X., Xu, W. et al. Integrating individual functional moieties of CXCL10 and CXCL11 into a novel chimeric chemokine leads to synergistic antitumor effects: a strategy for chemokine-based multi-target-directed cancer therapy. Cancer Immunol Immunother 59, 1715–1726 (2010). https://doi.org/10.1007/s00262-010-0901-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-010-0901-6